Los Angeles Capital Management
CAI

Los Angeles Capital Management’s Caris Life Sciences CAI Stock Holding History

Los Angeles Capital Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.5M Buy
3,958,531
+1,668,929
+73% +$29.9M 0.26% 82
2026
Q1 		$40.9M Buy
2,289,602
+2,289,037
+405,139% +$50M 0.16% 122
2025
Q4 		$17.6K Buy
+565
New +$15.9K ﹤0.01% 1913

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Los Angeles Capital Management's CAI Position: Q2 2026 in Review

Los Angeles Capital Management increased its Caris Life Sciences (CAI) stake by 73% in Q2 2026, buying an estimated $29.9M and bringing the position to 3,958,531 shares worth $70.5M. The position accounts for 0.26% of the portfolio, ranked #82.

Los Angeles Capital Management first reported a position in CAI in Q4 2025 and has held it in 3 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Los Angeles Capital Management held 3,958,531 shares of Caris Life Sciences worth $70.5M as of Q2 2026.
  • Los Angeles Capital Management bought 1,668,929 Caris Life Sciences shares in Q2 2026, an estimated $29.9M.
  • Caris Life Sciences made up 0.26% of Los Angeles Capital Management's portfolio in Q2 2026, its #82 holding.
  • Los Angeles Capital Management first reported a position in Caris Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.